Valuation: Haleon plc

Market Cap 27.99B 37.43B 33.52B 30.93B 52.33B 3,564B 53.18B 369B 147B 1,865B 140B 137B 5,908B P/E 2026 *
16.5x
P/E 2027 * 14.5x
Enterprise Value 34.88B 46.64B 41.78B 38.54B 65.22B 4,442B 66.27B 460B 183B 2,324B 175B 171B 7,362B EV / Sales 2026 *
3.06x
EV / Sales 2027 * 2.88x
Free-Float
98.31%
Yield 2026 *
2.55%
Yield 2027 * 2.81%
1 day-14.30%
1 week-17.36%
Current month-4.78%
1 month-5.51%
3 months-16.63%
6 months-7.85%
Current year-15.23%
1 week 8.38
Extreme 8.38
10.32
1 month 8.38
Extreme 8.38
10.4
Current year 8.38
Extreme 8.38
11.28
1 year 8.38
Extreme 8.38
11.28
3 years 7.7
Extreme 7.695
11.42
5 years 5.59
Extreme 5.59
11.42
10 years 5.59
Extreme 5.59
11.42
Manager TitleAgeSince
Chief Executive Officer 59 22/07/2021
Director of Finance/CFO 58 01/11/2024
Chief Tech/Sci/R&D Officer 63 01/08/2025
Director TitleAgeSince
Director/Board Member 59 23/05/2022
Chairman 71 01/01/2026
Director/Board Member 59 18/07/2022
Change 5-day change 1-year change 3-year change Capi.($)
-14.30%-17.36% - - 43.85B
+6.63%+5.13%+68.86%+145.20% 1,148B
+1.53%+2.84%+47.48%+89.01% 652B
+1.68%+1.96%+29.16%+109.31% 505B
+0.73%+2.47%+53.85%+68.96% 384B
+3.83%-0.62%+69.01%+42.32% 348B
+2.38%+4.27%+33.81%+57.95% 294B
+2.26%+3.47%+5.21%+28.92% 264B
+1.97%+3.01%+57.91%+76.14% 244B
+4.03%+5.36%+39.76%+116.14% 197B
Average +0.68%+1.39%+45.00%+81.55% 448.57B
Weighted average by Cap. +2.07%+1.50%+50.23%+95.97%

Financials

2026 *2027 *
Net sales 11.39B 15.24B 13.65B 12.59B 21.31B 1,451B 21.65B 150B 59.92B 759B 57.18B 55.96B 2,405B 11.87B 15.87B 14.22B 13.12B 22.2B 1,512B 22.55B 156B 62.43B 791B 59.57B 58.3B 2,506B
Net income 1.72B 2.31B 2.07B 1.91B 3.22B 220B 3.28B 22.73B 9.07B 115B 8.65B 8.47B 364B 1.93B 2.58B 2.31B 2.13B 3.61B 246B 3.67B 25.47B 10.16B 129B 9.69B 9.49B 408B
Net Debt 6.89B 9.22B 8.25B 7.62B 12.89B 878B 13.09B 90.86B 36.25B 459B 34.59B 33.85B 1,455B 6.21B 8.3B 7.43B 6.86B 11.61B 790B 11.79B 81.82B 32.64B 414B 31.15B 30.48B 1,310B
Projected Income Statement - Annual - Haleon plc
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
29/10/26 $8.570 -14.30% 56,762,932
28/10/26 $10.00 -0.79% 22,189,962
27/10/26 $10.08 -1.18% 15,855,215
26/10/26 $10.20 -0.68% 15,270,635
23/10/26 $10.27 -0.96% 15,066,423
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Haleon plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.177GBP
Average target price
4.179GBP
Spread / Average Target
+31.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Haleon plc